211374-82-2

Upstream product

• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 67579-92-4 3-methoxy-4-nitrobenzoic acid chloride 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 92241-87-7 3-methoxy-4-nitrobenzamide 

Downstream Products

• 1377582-20-1 3-methoxy-4-thioureido-benzamide 
• 1022968-27-9 C₁₂H₁₀Cl₂N₄O₂ 

Relevant academic research and scientific papers

STING AGONIST COMPOUNDS AND METHODS OF USE

The present disclosure relates to STING (Stimulator of Interferon Genes) agonist compounds, methods of making the compounds and their methods of use.

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

NOVEL USE OF THIENOPYRIMIDINES

The present invention relates to the use of thienopyrimidine compounds for the production of pharmaceutical compositions for the treatment of inflammatory diseases.

THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.